Fluspirilene (CAS 1841-19-6) Suppliers and Product Information

Fluspirilene is a dopamine D2 and D3 receptor antagonist. It is also known as McN-JR 6218, R 6218, and Redeptin. Fluspirilene is used as a neuroleptic drug and has potential applications in the treatment of schizophrenia and as an antipsychotic.

Fluspirilene is a potent non-competitive antagonist of agonist-activated L-type calcium channels (IC50 = 0.03 μM). It has been used in research as a calcium channel blocker and has potential applications in studying human ether-a-go-go related gene (HERG).

Frequently Asked Questions about Fluspirilene

Q: What is the primary use of Fluspirilene?

A: Fluspirilene is primarily used for supportive therapy of patients suffering from chronic mental illnesses after treatment in the hospital. It is suitable for use in ambulatory practice due to the lack of expressed hypno-sedative effects.

Q: How does Fluspirilene work?

A: Fluspirilene acts as a dopamine D2 and D3 receptor antagonist. It also functions as a potent non-competitive antagonist of agonist-activated L-type calcium channels.

Q: Are there any potential applications of Fluspirilene beyond its use as an antipsychotic?

A: Yes, Fluspirilene has shown potential as an anti-cancer agent, particularly in treating human hepatocellular carcinoma. It has been found to inhibit the activity of cyclin-dependent kinase 2 (CDK2).

Q: How is Fluspirilene typically administered?

A: In animal studies, Fluspirilene has been administered intramuscularly. However, specific dosing and administration methods for human use should be determined by healthcare professionals.